drugset
drugset / Trial / NCT05033587

Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.

NCT05033587 ↗

Phase 2 Unknown 28 enrolled The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, open-label single-arm, exploratory, two-stage design trial, aiming to investigate safety and efficacy of AK105 with anlotinib and radiotherapy adjuvant therapy in MGMT unmethylated newly diagnosed glioblastoma.

Timeline

Start
2021-09
Primary completion
2023-05-01
Completion
2023-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg Oral
Subject Penpulimab Monoclonal antibody 200 mg Intravenous

Indications

glioblastoma